Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

101.32 -0.77 (-0.75%)
Streaming Delayed Price Updated: 12:10 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis Ag ADR

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
20 21 Next >
FDA Gives Approval For Novartis' Tafinlar + Mekinist Broadens BRAF/MEK Cancer Combo Use
Via Benzinga
Precision BioSciences (DTIL) Stock Treks Higher on Novartis Deal
DTIL stock is advancing in early trading today after Precision BioScience announced a partnership with Novartis, a leading drug maker. 
Via InvestorPlace
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Precision BioSciences Shares Are Surging Today
Via Benzinga
Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability
Via Benzinga
New Data Shows Novartis' Kisqali Extends Survival In Postmenopausal Breast Cancer Setting
Via Benzinga
Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial
Via Benzinga
Novartis: Q1 Earnings Insights
Novartis (NYSE:NVS) reported its Q1 earnings results on Tuesday, April 26, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Sylvester Feddes joins the 2022 Leading Entrepreneurs of the World Conference
The Country President of Novartis Colombia will speak at 1BusinessWorld’s Leading Entrepreneurs of the World Conference about leading diversity and inclusion in a virtual environment 
Via News Direct
Pfizer's Ibrance Fails To Extend Overall Survival In Newly Diagnosed Breast Cancer Setting
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
6 Dividend Stocks With High Yields and Low P/E Ratios
These 6 dividend stocks have yields greater than 2.5% and P/E ratios lower than 16x with a positive earnings growth forecast for 2023. 
Via InvestorPlace
Here's The Surprising Source Of Novartis' First-Quarter Sales Growth
An unexpected business contributed 8% to Novartis' first-quarter sales growth. 
Via Investor's Business Daily
Earnings Scheduled For April 26, 2022
Companies Reporting Before The Bell • First American Financial (NYSE:FAF) is estimated to report quarterly loss at $0.09 per share on revenue of $46.41 million. 
Via Benzinga
Analyzing Novartis's Short Interest
Novartis's (NYSE:NVS) short percent of float has risen 3.57% since its last report. The company recently reported that it has 6.56 million shares sold short, which is 0.29% of all... 
Via Benzinga
Current Report: Novartis (NVS)
Novartis’s price per share was $87.81 as of yesterday's market close. One year ago its price was $88.85. 
Via Talk Markets
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
3 Undervalued Stocks to Buy Before You Sell in May and Go Away
If you really decide to sell in May and go away, you may miss out some profits from these undervalued stocks to buy. 
Via InvestorPlace
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped. 
Via Investor's Business Daily
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data
Via Benzinga
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook
Via Benzinga
Novartis Earnings Preview
Novartis (NYSE:NVS) is set to give its latest quarterly earnings report on Tuesday, 2022-04-26. Here's what investors need to know before the announcement. Analysts estimate that Novartis will report... 
Via Benzinga
EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting
Via Benzinga
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.